A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia
Genes, Chromosomes and Cancer · 2024
DOI: 10.1002/gcc.23252 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Ozgur Can Eren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Janus Kinase 2. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Memorial Sloan Kettering Cancer Center, National Institute of Health MSK Cancer Center Support Grant/Core Grant, Memorial Sloan-Kettering Cancer Center.
Abstract (Originalsprache)
T‐cell prolymphocytic leukemia (T‐PLL) is a rare and aggressive mature T‐cell malignancy characterized by marked lymphocytosis, B symptoms, lymphadenopathy, and hepatosplenomegaly. There is no standard treatment approach, and in the absence of an allogeneic transplant, the prognosis remains poor. The disease‐defining cytogenetic abnormality in T‐PLL is the juxtaposition of the TCL1‐ family oncogene to the TCR gene enhancer locus primarily due to an inversion of chromosome 14, that is, inv(14). The application of next‐generation sequencing technologies led to the discovery of highly recurrent gain‐of‐function mutations in JAK1/3 and STAT5B in over 70% of T‐PLL providing opportunities for therapeutic intervention using small molecule inhibitors. Additional genetic mechanisms that may contribute to the pathogenesis of T‐PLL remain unknown. Herein we describe the identification of a novel gene fusion SMCHD1::JAK2 resulting from a translocation between chromosome 9 and 18 involving SMCHD1 exon 45 and JAK2 exon 14 (t(9;18)(p24.1;p11.32)(chr9:g.5080171::chr18:g.2793269)), a previously undescribed genetic event in a patient with T‐PLL harboring the key disease defining inv(14) resulting in rearrangement of TCL1 and TRA/D . In this manuscript, we describe the clinical and genetic features of the patient's disease course over a 25‐month post‐treatment duration using ruxolitinib and duvelisib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Diagnostic Molecular Pathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Ozgur Can Eren
Förderung
- Memorial Sloan Kettering Cancer Center
- National Institute of Health MSK Cancer Center Support Grant/Core Grant
- Memorial Sloan-Kettering Cancer Center
Zitieren
APA
Eren, O. C., Stuver, R., Zhou, T., Zaidinski, M., Moskowitz, A. J., Horwitz, S. M., Ewalt, M. D., Zhang, Y., & Lim, M. S. (2024). A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23252
Vancouver
Eren OC, Stuver R, Zhou T, Zaidinski M, Moskowitz AJ, Horwitz SM, et al. A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia. Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.23252
BibTeX
@article{Eren2024,
author = {Eren, Ozgur Can and Stuver, Robert and Zhou, Ting and Zaidinski, Michael and Moskowitz, Alison J and Horwitz, Steven M and Ewalt, Mark D and Zhang, Yanming and Lim, Megan S},
title = {A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia},
journal = {Genes, Chromosomes and Cancer},
year = {2024},
doi = {10.1002/gcc.23252}
}
EUVIMED